Company Overview and News

 
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update

15h seekingalpha
Glenview Capital Management’s 13F portfolio value decreased from $18.50B to $17.10B this quarter. The number of positions decreased from 58 to 52.

 
Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis

2018-05-23 zacks
Eli Lilly & Company (LLY - Free Report) announced that the FDA has approved the inclusion of additional data on the label of its psoriasis injection, Taltz. With the latest approval, Taltz label will now include data for psoriasis involving the genital area, which impacts roughly 63% of psoriasis patients over the course of their disease.

 
Is Celgene's Stock A Buy The Dip Opportunity?

2018-05-23 seekingalpha
Celgene's stock is in a downtrend but selling volume picked up on May 21 for no apparent reason.

 
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo

2018-05-22 zacks
Chicago, IL – May 22, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Procter & Gamble (PG - Free Report) , AbbVie (ABBV - Free Report) , McDonald’s (MCD - Free Report) and PepsiCo (PEP - Free Report) .

 
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo

2018-05-22 zacks
Chicago, IL – May 22, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Procter & Gamble (PG - Free Report) , AbbVie (ABBV - Free Report) , McDonald’s (MCD - Free Report) and PepsiCo (PEP - Free Report) .

 
Three Stocks to Buy to Find Gains in Today’s Market

2018-05-22 investorplace
The market has been a wobbly place so far this year, making picking investments a tricky business. However, that doesn’t mean there aren’t some good buys out there that can withstand a bit of turbulence and deliver impressive gains. If you’ve got some cash to spare and you’re wondering what to invest in now, here are three options to consider.

 
Roche (RHHBY) Announces Positive Data on Hemophilia Drug

2018-05-21 zacks
Roche (RHHBY - Free Report) announced full results from the phase III study, HAVEN 3, evaluating haemophilia A drug Hemlibra (emicizumab).

 
Top Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo

2018-05-21 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 17 major stocks, including Procter & Gamble (PG), AbbVie (ABBV), McDonald’s (MCD) and PepsiCo (PEP). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

1
Roth IRAs From A Retiree's Perspective - Great For The Young And Young At Heart

2018-05-18 seekingalpha
Roth IRAs are going to be the most fun to write about of any of the postings in this series. There are just so many benefits to Roth accounts that they are fun to think about. It isn't just about taxes, but they're good place to start.

 
Bear of the Day: Scotts Miracle-Gro (SMG)

2018-05-17 zacks
Known for its popular lawn and garden care products, Scotts Miracle-Gro Co. (SMG - Free Report) is one of the most recognized names in the gardening industry. Its U.S. brands include Scotts, Miracle-Gro, Ortho, and Smith & Hawken. The company’s customers are wide-ranging, from home improvement centers and hardware chains to nurseries and specialty crop growers.

 
Jane's April Dividend Income Tracker - Retirement Accounts

2018-05-15 seekingalpha
This is the second month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her combined dividend income totaled $1,300.03.

 
Trump’s Attempt to Shame Drugmakers Shows Medicare Costs Soaring - Bloomberg

2018-05-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

4
7 ‘Strong Buy’ Stocks Analysts Are Upgrading Now

2018-05-14 investorplace
Analysts reiterate their stock recommendations quite a bit. So when a stock is upgraded, or more rarely, downgraded, the market takes note. This is especially the case for a market-leading stock like Facebook, Inc. (NASDAQ:FB) — see below!

8
30 Marijuana Stocks to Buy as the Future Turns Green

2018-05-14 investorplace
When it comes to cannabis, we’ve come a long way since former President Bill Clinton denied ever inhaling. With the previous presidential administration’s frankness on the matter, marijuana has become more blasé. Naturally, marijuana stocks have also increased in popularity, where we have more choices today than was previously thought possible.

 
A Behind-the-Scenes Look at Takeda Pharma’s Takeover of Shire

2018-05-14 biospace
The ink is still drying on the contracts for Japan’s Takeda Pharmaceutical’s acquisition of Dublin-based Shire for about $62.2 billion, but company executives are sharing some of the “inside baseball” about what went on behind the scenes of the deal.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...